Following the success of the MRS and AMS, there was a move to develop an instrument that measured health-related quality of life (HRQoL) specifically related to changes due to the use of sex-steroid hormone in women. Our research group hypothesised that several domains could be explored assessing the known pharmacological effects of sex-steroid hormones and the reported short-term outcomes of treatment with such hormones including; psychological effects, sexual symptoms, (pre-) menstrual problems and pharmacological hormone-related effects on certain organs such as breast, hair and skin.
The scale was designed for all women, irrespective of age, ethnicity, social class or health status.
- Patient-reported outcome scale
- High acceptability among women
- Applicable in clinical and observational research
- Ability to compare between groups and over time
- Use as an outcome measure